Aldebaran Financial Inc. Sells 556 Shares of Johnson & Johnson (NYSE:JNJ)

Aldebaran Financial Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,541 shares of the company’s stock after selling 556 shares during the quarter. Johnson & Johnson comprises about 1.7% of Aldebaran Financial Inc.’s portfolio, making the stock its 17th biggest position. Aldebaran Financial Inc.’s holdings in Johnson & Johnson were worth $1,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. PVG Asset Management Corp bought a new position in Johnson & Johnson in the second quarter valued at about $931,000. Heartland Bank & Trust Co lifted its position in Johnson & Johnson by 6.7% during the 2nd quarter. Heartland Bank & Trust Co now owns 8,910 shares of the company’s stock valued at $1,302,000 after purchasing an additional 559 shares during the period. SPC Financial Inc. boosted its stake in shares of Johnson & Johnson by 6.6% in the 2nd quarter. SPC Financial Inc. now owns 18,128 shares of the company’s stock valued at $2,650,000 after purchasing an additional 1,120 shares during the last quarter. Advisory Alpha LLC raised its stake in shares of Johnson & Johnson by 6.8% during the second quarter. Advisory Alpha LLC now owns 5,743 shares of the company’s stock worth $839,000 after buying an additional 367 shares during the last quarter. Finally, Truist Financial Corp lifted its holdings in Johnson & Johnson by 4.9% in the second quarter. Truist Financial Corp now owns 2,122,856 shares of the company’s stock valued at $310,277,000 after buying an additional 98,903 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on JNJ. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.4 %

Shares of JNJ stock opened at $162.02 on Tuesday. The company has a market capitalization of $389.93 billion, a price-to-earnings ratio of 10.10, a P/E/G ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The firm has a fifty day moving average of $162.30 and a 200-day moving average of $154.18. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $2.80 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.